Iterum Therapeutics PLC
NASDAQ:ITRM
Cash Flow Statement
Cash Flow Statement
Iterum Therapeutics PLC
Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | ||||||||||||||||||||||||||
Net Income |
(29)
|
(36)
|
(45)
|
(62)
|
(77)
|
(85)
|
(97)
|
(104)
|
(103)
|
(99)
|
(84)
|
(64)
|
(52)
|
(135)
|
(115)
|
(99)
|
(92)
|
4
|
(11)
|
(44)
|
(44)
|
(51)
|
(56)
|
(31)
|
(38)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
3
|
3
|
2
|
2
|
2
|
2
|
2
|
|
Other Non-Cash Items |
0
|
0
|
1
|
1
|
1
|
2
|
2
|
2
|
3
|
6
|
11
|
17
|
22
|
112
|
92
|
80
|
74
|
(21)
|
(5)
|
24
|
22
|
26
|
27
|
(9)
|
(5)
|
|
Cash Taxes Paid |
(0)
|
(0)
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
(0)
|
0
|
0
|
|
Cash Interest Paid |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Change in Working Capital |
(2)
|
(2)
|
4
|
(1)
|
(2)
|
3
|
9
|
17
|
18
|
(2)
|
(17)
|
(21)
|
(25)
|
(5)
|
(1)
|
(5)
|
(0)
|
(4)
|
(3)
|
(0)
|
2
|
(1)
|
2
|
7
|
3
|
|
Cash from Operating Activities |
(31)
N/A
|
(37)
-20%
|
(40)
-9%
|
(62)
-55%
|
(77)
-24%
|
(81)
-4%
|
(86)
-7%
|
(84)
+2%
|
(82)
+3%
|
(94)
-15%
|
(90)
+5%
|
(69)
+23%
|
(55)
+20%
|
(28)
+48%
|
(23)
+19%
|
(22)
+2%
|
(16)
+29%
|
(18)
-14%
|
(16)
+11%
|
(17)
-4%
|
(18)
-11%
|
(25)
-33%
|
(26)
-6%
|
(31)
-18%
|
(39)
-28%
|
|
Investing Cash Flow | ||||||||||||||||||||||||||
Capital Expenditures |
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
|
Other Items |
(31)
|
(21)
|
(17)
|
(31)
|
(9)
|
17
|
51
|
69
|
40
|
5
|
0
|
0
|
0
|
(34)
|
(55)
|
(50)
|
(55)
|
(11)
|
(6)
|
5
|
14
|
10
|
30
|
14
|
23
|
|
Cash from Investing Activities |
(32)
N/A
|
(22)
+31%
|
(17)
+23%
|
(31)
-84%
|
(9)
+72%
|
17
N/A
|
51
+199%
|
69
+35%
|
40
-42%
|
5
-88%
|
0
-100%
|
(0)
N/A
|
(0)
N/A
|
(34)
-339 200%
|
(55)
-62%
|
(50)
+9%
|
(55)
-9%
|
(11)
+80%
|
(6)
+48%
|
5
N/A
|
14
+173%
|
9
-32%
|
30
+213%
|
14
-52%
|
23
+64%
|
|
Financing Cash Flow | ||||||||||||||||||||||||||
Net Issuance of Common Stock |
46
|
78
|
106
|
106
|
108
|
76
|
1
|
4
|
3
|
50
|
54
|
53
|
70
|
111
|
109
|
106
|
90
|
1
|
(0)
|
0
|
0
|
1
|
1
|
1
|
1
|
|
Net Issuance of Debt |
0
|
0
|
15
|
15
|
15
|
0
|
0
|
0
|
(1)
|
(3)
|
(3)
|
(5)
|
(5)
|
(6)
|
(6)
|
(6)
|
(7)
|
(7)
|
(6)
|
(4)
|
(2)
|
0
|
0
|
0
|
0
|
|
Cash from Financing Activities |
46
N/A
|
78
+70%
|
121
+55%
|
121
N/A
|
122
+1%
|
90
-26%
|
1
-98%
|
4
+214%
|
2
-54%
|
48
+2 224%
|
51
+6%
|
48
-4%
|
64
+33%
|
106
+64%
|
102
-3%
|
100
-2%
|
83
-17%
|
(6)
N/A
|
(6)
+10%
|
(4)
+30%
|
(2)
+53%
|
1
N/A
|
1
+30%
|
1
+1%
|
1
+18%
|
|
Change in Cash | ||||||||||||||||||||||||||
Effect of Foreign Exchange Rates |
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Net Change in Cash |
(16)
N/A
|
20
N/A
|
64
+226%
|
28
-57%
|
36
+31%
|
26
-27%
|
(34)
N/A
|
(11)
+68%
|
(40)
-270%
|
(41)
-4%
|
(39)
+6%
|
(20)
+48%
|
10
N/A
|
43
+337%
|
24
-44%
|
27
+13%
|
13
-54%
|
(35)
N/A
|
(27)
+22%
|
(16)
+43%
|
(6)
+59%
|
(15)
-128%
|
5
N/A
|
(16)
N/A
|
(15)
+4%
|
|
Free Cash Flow | ||||||||||||||||||||||||||
Free Cash Flow |
(31)
N/A
|
(37)
-18%
|
(40)
-9%
|
(62)
-54%
|
(77)
-24%
|
(81)
-4%
|
(86)
-7%
|
(84)
+2%
|
(82)
+3%
|
(94)
-15%
|
(90)
+5%
|
(69)
+23%
|
(55)
+20%
|
(28)
+48%
|
(23)
+19%
|
(22)
+2%
|
(16)
+29%
|
(18)
-14%
|
(16)
+11%
|
(17)
-4%
|
(19)
-11%
|
(25)
-33%
|
(26)
-6%
|
(31)
-18%
|
(39)
-28%
|